This is extremely good! It means: A-7 is working very good!
In the company's Phase 3 registration trial of Allovectin(R) in patients with metastatic melanoma, enrollment was completed in February 2010. With a maximum two-year treatment period, the last patients will receive their final treatments in February 2012. Based on the latest available information on overall number of deaths, the company expects to reach the target number of death events for the secondary endpoint (overall survival) in late 2012. Data collection and independent adjudication for the primary endpoint (response rate at 24 weeks or more after randomization) will be conducted in parallel, and top-line data for both endpoints is expected to be released in late 2012. Additional details will be provided in today's conference call.
Of course you're right therman that the news is good. I suspected this might happen. And that we'd get yet ANOTHER buying opportunity which I do not need. We'll see.
Treadleon, I posed the question long ago as to whether they would release the response data early if the events came too slowly. And whether the market would interpret not releasing that data as a negative. We'll see again. I hope Vijay clarifies their thinking regarding this subject. A sceptic would ask, Why not release the good news if it's available? Because the all important OS might not be as successful and that would create a crash-back? Perhaps, but we've got to feel even better about the survival data now. Heck, it could get pushed back again come December!